ESC 365 - Peroxiredoxin-4 and beta-hydroxybutyrate after SGLT2 inhibitor treatment in heart failure with preserved ejection fraction

HFA Premium Access

Peroxiredoxin-4 and beta-hydroxybutyrate after SGLT2 inhibitor treatment in heart failure with preserved ejection fraction

Session: Diagnosis and prognosis of HFpEF

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Miss A. Achten (Maastricht, NL)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Miss Anouk Achten

Cardiovascular Research Institute Maastricht (CARIM), Maastricht (Netherlands (The))

0 follower

3 more presentations in this session

Frailty and cardiovascular comorbidities as predictors of short-term outcomes in HFpEF and HFmrEF patients: a retrospective cohort analysis

Speaker: Associate Professor A. Briasoulis (Athens, GR)

Differences in heart failure with preserved ejection fraction diagnostic and therapeutic practices between physicians from europe and the middle east and north africa: an international survey

Speaker: Professor H. Alarfaj (Riyadh, SA)

Incident atrial fibrillation in heart failure with preserved or reduced ejection fraction: the single centre experience

Speaker: Assistant Professor M. Pandrc (Belgrade, RS)

Access the full session

Diagnosis and prognosis of HFpEF

Speakers: Miss A. Achten, Associate Professor A. Briasoulis, Professor H. Alarfaj, Assistant Professor M. Pandrc

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources